Investigating the surface characteristics of nano delivery systems and their interactions with plasma is essential in determining the post-delivery fate of a drug product.

The National Cancer Institute’s (NCI) Nanotechnology Characterization Laboratory (NCL) conducts preclinical characterization, including physicochemical in vitro and in vivo analysis of nanoparticles, intended as cancer therapeutics and diagnostics.

Join our webinar featuring guest speaker Dr. Jeffrey D. Clogston, Principal Scientist, NCL to learn about:

  • The methodology and analytical techniques used to characterize nano delivery systems (including the testing of more than 425 nanotechnology-based candidate cancer treatments and diagnostics)
  • Characterization techniques such as dynamic and static light scattering, zeta potential, and asymmetric-flow field-flow fractionation (AF4)
  • How these techniques are used to assess the stability of nano delivery systems in plasma

Summary

Measurement type:
Zeta potential
Date:
January 21 2021 - January 21 2021
Time:
10:30 - 11:30
Eastern Time [US & Canada]
Event type:
Webinar - Live
Language:
English
Products:
Zetasizer Advance Range
NanoSight LM10
Technology:
Light Scattering
Static Light Scattering
Dynamic Light Scattering
Industry:
Biologics
Pharmaceutical
Nanomaterials

Speakers

About your speakers:

Dr. Jeffrey D. Clogston

Dr. Jeffrey D. Clogston is a Principal Scientist and the Head of the Physicochemical Characterization Section at the Nanotechnology Characterization Laboratory (NCL). National Cancer Institute (NCI) established the NCL to perform preclinical efficacy and toxicity testing of nanoparticles. Dr. Clogston conducts physicochemical characterization and standardization of nanoparticles, develops new analytical methodology for critical quality attributes, and assesses current instrumentation for nanoparticle characterization. Prior to joining the NCL in March 2006, Dr. Clogston received his Ph.D. in Chemical Engineering from The Ohio State University. His research dissertation was on the application of the lipidic cubic phase for drug delivery, wastewater remediation, and membrane protein crystallization. His areas of expertise include physicochemical characterization of and in vitro release from lipid-based drug delivery systems, analytical methodology, and protein and lipid biochemistry.

Dr. Ragy Ragheb

Dr. Ragy Ragheb is a Technical Specialist/Application Scientist with Malvern Panalytical specializing in light scattering technologies and GPC/SEC product lines. Dr. Ragheb received his Ph.D. in Macromolecular Science and Engineering from Virginia Polytechnic Institute and State University and completed his post-doctoral work in Biomedical Engineering at Yale University. His research focused on the fabrication and characterization of various synthetic and metal-based nanoparticle systems for theranostic and drug delivery applications.

More information

What will you learn?

  • The methodology and analytical techniques used to characterize nano delivery systems (including the testing of more than 425 nanotechnology-based candidate cancer treatments and diagnostics)
  • Characterization techniques such as dynamic and static light scattering, zeta potential, and asymmetric-flow field-flow fractionation (AF4)
  • How these techniques are used to assess the stability of nano delivery systems in plasma